Announcement on Resignation of Securities Affairs Representative
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Resignation of Securities Affairs Representative
Filed with SSE · · 1 page · Chinese
Release
Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix
Earlier from Sichuan Biokin Pharmaceutical
- Announcement on Voluntary Disclosure of First Subject Enrollment in the Phase III Clinical Trial of Lenconelontuzumab/Yizekang (BL-B01D1/iza-bren) Combination Therapy for First-Line Extensive-Stage Small Cell Lung Cancer
- Announcement on Voluntary Disclosure of the Approval for Market Launch of Izaberonramab (BL-B01D1/iza-bren)
- Announcement on Voluntary Disclosure of Receiving Drug Clinical Trial Approval Notice for BL-M14D1 for Injection (DLL3 ADC) in Combination Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer
- Announcement on Receipt of the Notice of Registration Acceptance from the National Association of Financial Market Institutional Investors
- Announcement on Voluntary Disclosure of the IND Application for the Phase III Clinical Trial of BL-M14D1 (DLL3 ADC) in Combination with Immunotherapy for First-Line Extensive-Stage Small Cell Lung Cancer Receiving FDA Clearance
Later from Sichuan Biokin Pharmaceutical
- Announcement on Progress in Repurchasing Shares
- Announcement on Implementation Results of Share Repurchase
- Announcement on Voluntary Disclosure of Approval of the Marketing Application for BL-B01D1/iza-bren for Treatment of Esophageal Cancer
- Announcement on Voluntary Disclosure of the Completion of First Subject Enrollment in the Phase III Clinical Trial of BL-B01D1/iza-bren for the Treatment of Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-Based Chemotherapy
- Announcement on the Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren (HER2 ADC) for Injection in Patients with HER2-Expressing Locally Advanced or Metastatic Biliary Tract Cancer Who Failed Platinum-Based Chemotherapy
Follow Sichuan Biokin Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Biokin Pharmaceutical